Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Sticking to them is your best bet for ensuring your Retatrutide maintains its specified purity and efficacy throughout your study
SURMOUNT-1 trial suggests that tirzepatide may have a promising future as a therapy for obesity, HF, and non-alcoholic fatty liver disease (NAFLD) [5, 8]
It's important to note that hypoglycaemia (low blood sugar) risk with semaglutide alone is low, but this risk increases when used in combination with insulin or sulfonylureas
This dual mechanism of action is the same as Eli Lillys Mounjaro, currently marketed for T2D and being tested for its effect on obesity
Onceweekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
